Cancer

Cover image for Vol. 122 Issue 24

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.649

ISI Journal Citation Reports © Ranking: 2015: 26/213 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 129
  1. Original Articles

    1. Disease Site

      Hematologic Malignancies
      MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma

      Toshifumi Takeuchi, Motoko Yamaguchi, Kyoko Kobayashi, Kana Miyazaki, Isao Tawara, Hiroshi Imai, Ryoichi Ono, Tetsuya Nosaka, Kyosuke Tanaka and Naoyuki Katayama

      Version of Record online: 4 DEC 2016 | DOI: 10.1002/cncr.30404

      • image
      • image

      The frequency of myeloid differentiation primary response 88 (MYD88) and CD79B gene mutations in CD5-positive diffuse large B-cell lymphoma (DLBCL) is lower than that in primary DLBCL occurring within sanctuary sites. Caspase recruitment domain family member 11 (CARD11) gene mutations are uncommon in patients with CD5-positive DLBCL.

  2. Editorials

    1. You have free access to this content
      Improving the safety and quality of cancer care

      Harry B. Burke

      Version of Record online: 2 DEC 2016 | DOI: 10.1002/cncr.30438

  3. Original Articles

    1. Disease Site

      Melanoma
      Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

      Dae Won Kim, Lauren E. Haydu, Aron Y. Joon, Roland L. Bassett Jr, Alan E. Siroy, Michael T. Tetzlaff, Mark J. Routbort, Rodabe N. Amaria, Jennifer A. Wargo, Jennifer L. McQuade, Jan Kemnade, Patrick Hwu, Scott E. Woodman, Jason Roszik, Kevin B. Kim, Jeffrey E. Gershenwald, Alexander J. Lazar and Michael A. Davies

      Version of Record online: 2 DEC 2016 | DOI: 10.1002/cncr.30463

      • image

      Although TP53 and BRAFNon-V600 mutations are common oncogenic mutations in non-acral cutaneous melanoma, very little is known about their clinical and pathological significance. This analysis of a large cohort of patients with advanced melanoma suggests that TP53 mutations are associated with improved outcomes in patients with advanced non-acral cutaneous melanoma. This is a surprising finding that warrants further evaluation in this disease.

    2. Hematologic Malignancies
      A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

      Kenneth R. Carson, Steven M. Horwitz, Lauren C. Pinter-Brown, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark A. Acosta, Andrei R. Shustov, Ranjana H. Advani, Tatyana A. Feldman, Mary Jo Lechowicz, Sonali M. Smith, Frederick Lansigan, Anil Tulpule, Michael D. Craig, John P. Greer, Brad S. Kahl, Joseph W. Leach, Neil Morganstein, Carla Casulo, Steven I. Park and Francine M. Foss

      Version of Record online: 2 DEC 2016 | DOI: 10.1002/cncr.30416

      • image
      • image
      • image
      • image

      There is no clear standard of care in the treatment of patients with peripheral T-cell lymphoma in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent.

    3. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission—Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

      Norbert-Claude Gorin, Myriam Labopin, Tomasz Czerw, Thomas Pabst, Didier Blaise, Pierre-Yves Dumas, Damir Nemet, William Arcese, Silvia Maria Trisolini, Depei Wu, Anne Huynh, Tsila Zuckerman, Ellen Meijer, Seckin Cagirgan, Jan Cornelissen, Mohamed Houhou, Emmanuelle Polge, Mohamad Mohty and Arnon Nagler

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30400

      • image

      For adult patients with acute myelocytic leukemia in first remission who undergo autograft, the combination of busulfan plus high-dose melphalan (BUMEL) results in a better outcomes than the historic combination of busulfan plus cyclophosphamide (BUCY), producing leukemia-free survival rates at 3 years of 55.4% versus 44.6% post BUCY, respectively (hazard ratio, 0.69; P = .005). Patients in molecular remission who undergo autograft after receiving BUMEL have a leukemia-free survival rate of 66%, supporting the use of BUMEL before autograft for patients in first molecular complete remission.

    4. Genitourinary Disease
      Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years

      Paul F. Pinsky, Philip C. Prorok, Kelly Yu, Barnett S. Kramer, Amanda Black, John K. Gohagan, E. David Crawford, Robert L. Grubb and Gerald L. Andriole

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30474

      • image

      Follow-up for prostate cancer mortality in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial has been extended to a median of 15 years from randomization. The findings continue to indicate no difference in prostate cancer mortality between arms with a rate ratio of 1.04 for the intervention arm versus the control arm. See also pages 000-000.

  4. Editorial

    1. Insights from the PLCO trial about prostate cancer screening

      Roman Gulati and Peter C. Albertsen

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30472

      Updated results from the US-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial show durability of earlier findings demonstrating that up to 6 rounds of annual prostate-specific antigen testing does not reduce prostate cancer mortality in comparison with historical screening practice. Although trials in Europe have estimated that certain screening programs can reduce prostate cancer mortality in comparison with no screening, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial demonstrates that there are limits to the benefit that can be achieved. See also pages 000-000.

  5. Original Articles

    1. Discipline

      Disparities Research
      Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase β and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma

      Meganathan P. Ramakodi, Karthik Devarajan, Elizabeth Blackman, Denise Gibbs, Danièle Luce, Jacqueline Deloumeaux, Suzy Duflo, Jeffrey C. Liu, Ranee Mehra, Rob J. Kulathinal and Camille C. Ragin

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30457

      • image
      • image
      • image
      • image
      • image

      African Americans with head and neck squamous cell carcinoma have higher levels of DNA polymerase β expression than white patients because of ancestry-related genetic factors. Integrative genomic analyses show that ancestry-related alleles can act as expression quantitative trait loci in head and neck squamous cell carcinoma, and they support the association of ancestry-related genetic factors with survival disparities in patients diagnosed with oral cavity and laryngeal cancer.

    2. Disease Site

      Skin
      Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors

      Ayse Selen Yilmaz, Hatice Gulcin Ozer, Jessica L. Gillespie, Dawn C. Allain, Madison N. Bernhardt, Karina Colossi Furlan, Leticia T.F. Castro, Sara B. Peters, Priyadharsini Nagarajan, Stephen Y. Kang, O. Hans Iwenofu, Thomas Olencki, Theodoros N. Teknos and Amanda Ewart Toland

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30459

      • image
      • image

      Exome and/or targeted deep sequencing analysis of 10 primary cutaneous squamous cell carcinoma (cSCC) and 18 metastatic cSCC samples demonstrated mutations in known skin cancer-related genes such as TP53 and NOTCH1. Combining frequency data from primary and metastatic cSCCs from the current study with those in the literature demonstrated a higher mutation frequency in TP53 and KMT2D in metastatic tumors compared with nonmetastatic cSCC samples.

  6. Communication

    1. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

      Julie E. Bauman, Ezra Cohen, Robert L. Ferris, David J. Adelstein, David M. Brizel, John A. Ridge, Brian O'Sullivan, Barbara A. Burtness, Lisa H. Butterfield, William E. Carson, Mary L. Disis, Bernard A. Fox, Thomas F. Gajewski, Maura L. Gillison, James W. Hodge, Quynh-Thu Le, David Raben, Scott E. Strome, Jean Lynn and Shakun Malik

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30449

      • image
      • image
      • image

      The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with head and neck squamous cell carcinoma. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies currently are being activated to accrual.

  7. Review Articles

    1. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review

      Hassan M. Moukhadder, Racha Halawi, Maria Domenica Cappellini and Ali T. Taher

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30462

      • image

      Hepatocellular carcinoma is an emerging morbidity in thalassemia. No guidelines have been established on the treatment of hepatocellular carcinoma in patients with thalassemia, but there is compelling evidence that systematic screening and prevention programs, in conjunction with appropriate iron chelation and viral hepatitis treatment, constitute the mainstay of management of this entity in thalassemia patients.

  8. Original Articles

    1. Discipline

      Disparities Research
      A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics

      Stacy N. Davis, Shannon M. Christy, Enmanuel A. Chavarria, Rania Abdulla, Steven K. Sutton, Alyssa R. Schmidt, Susan T. Vadaparampil, Gwendolyn P. Quinn, Vani N. Simmons, Chukwudi B. Ufondu, Chitra Ravindra, Ida Schultz, Richard G. Roetzheim, David Shibata, Cathy D. Meade and Clement K. Gwede

      Version of Record online: 1 DEC 2016 | DOI: 10.1002/cncr.30481

      • image

      Disparities in colorectal cancer screening among medically underserved communities are addressed in an intervention to increase the uptake of the fecal immunochemical test (FIT). Although there do not appear to be any significant differences in FIT uptake between the targeted and nontargeted intervention conditions, high FIT uptake rates suggest that the provision of a FIT kit removes a crucial barrier to care.

    2. Disease Site

      Breast Disease
      Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study

      Nour Sneige, Kenneth R. Hess, Asha S. Multani, Yun Gong and Nuhad K. Ibrahim

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30460

      • image
      • image
      • image
      • image
      • image
      • image

      Equivocal human epidermal growth factor receptor 2 (HER2) results resemble HER2-negative cases, not HER2-amplified cases. Alternative chromosome 17 probes are not effective in determining the HER2 status, so their use is not recommended in daily clinical practice.

  9. Correspondence

    1. Sexual quality of life in the cancer continuum

      Balasubramanian Srilatha, Jayne Chiara Leong and Yew Jin Ong

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30448

    2. Reply to Sexual quality of life in the cancer continuum

      Sarah E. Jackson, Andrew Steptoe and Abigail Fisher

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30447

  10. Original Articles

    1. Discipline

      Survivorship
      Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors

      Melinda L. Irwin, Brenda Cartmel, Maura Harrigan, Fangyong Li, Tara Sanft, Laura Shockro, Keelin O'Connor, Nancy Campbell, Sara M. Tolaney, Erica L. Mayer, Rachel Yung, Rachel A. Freedman, Ann H. Partridge and Jennifer A. Ligibel

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30456

      • image
      • image
      • image

      The LIVESTRONG at the Young Men's Christian Association (YMCA) exercise program is safe and effective for improving physical activity, fitness, fatigue, and quality of life in cancer survivors. This program has the potential to impact thousands of survivors across the YMCA network and could lead to improvements in disease and psychosocial outcomes in the growing population of cancer survivors.

    2. Medical Oncology
      Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma

      Mette S. Mortensen, Mikkel Bandak, Maria GG. Kier, Jakob Lauritsen, Mads Agerbæk, Niels V. Holm, Hans von der Maase and Gedske Daugaard

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30458

      • image
      • image
      • image

      The treatment of patients with high-risk, stage I seminoma has shifted from adjuvant radiotherapy to surveillance in many centers. Although the risk of disease recurrence is much higher after surveillance, the authors report no differences in overall survival or in the risk of receiving >1 treatment line when comparing the patients followed with surveillance with those who received adjuvant radiotherapy.

  11. Review Articles

    1. A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment

      Ya-Chen Tina Shih and Chun-Ru Chien

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30423

      • image
      • image

      Cost communication is often welcomed by patients and physicians, but such communication does not happen frequently in oncology practice. Having transparent cost information not only will facilitate patient-physician cost communication but also will improve its effectiveness.

  12. Original Articles

    1. Discipline

      Psychosocial Oncology
      Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis

      Karen L. Syrjala, Steven K. Sutton, Heather S.L. Jim, Jennifer M. Knight, William A. Wood, Stephanie J. Lee, Paul B. Jacobsen, Muneer H. Abidi and Jean C. Yi

      Version of Record online: 28 NOV 2016 | DOI: 10.1002/cncr.30454

      Although emotional distress is widely recognized as contributing to the suffering of patients with cancer, to the authors' knowledge few measures of the sources and intensity of emotional distress specific to cancer and its treatment have been evaluated in patients over time. In psychometric testing with patients undergoing hematopoietic cell transplantation before transplantation and at 100 days and 180 days after, the Cancer and Treatment Distress measure appears to be reliable and valid, and thus could be useful for tracking multiple dimensions of distress, determining the need for psychosocial treatment, and evaluating response to treatment.

    2. Disease Site

      Soft Tissue and Bone Sarcoma
      Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors

      Angela C. Hirbe, Madhurima Kaushal, Mukesh Kumar Sharma, Sonika Dahiya, Melike Pekmezci, Arie Perry and David H. Gutmann

      Version of Record online: 22 NOV 2016 | DOI: 10.1002/cncr.30455

      • image

      Neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors are deadly sarcomas with few treatment options. Using clinical-grade genomic profiling, tyrosine kinase 2 (TYK2) was identified as a new gene that is mutated and overexpressed in malignant peripheral nerve sheath tumors.

    3. Gastrointestinal Disease
      Clinical and genetic determinants of ovarian metastases from colorectal cancer

      Karuna Ganesh, Ronak H. Shah, Efsevia Vakiani, Garrett M. Nash, Hugh P. Skottowe, Rona Yaeger, Andrea Cercek, Anne Lincoln, Christina Tran, Neil H. Segal, Diane L. Reidy, Anna Varghese, Andrew S. Epstein, Yukio Sonoda, Dennis Chi, Jose Guillem, Larissa Temple, Philip Paty, Jaclyn Hechtman, Jinru Shia, Martin Weiser, Julio Garcia Aguilar, Nancy Kemeny, Michael F. Berger, Leonard Saltz and Zsofia K. Stadler

      Version of Record online: 22 NOV 2016 | DOI: 10.1002/cncr.30424

      • image
      • image
      • image
      • image

      The results of this large retrospective study of patients with ovarian metastases from colorectal cancer demonstrate that patients who undergo complete surgical resection of all macroscopic metastatic disease have a better prognosis than those who undergo incomplete surgical resection. In addition, the authors identify tumor mutations specifically associated with ovarian metastases and with poor survival, thus laying the foundation for future genetic risk stratification of candidates for oophorectomy.

  13. Review Articles

    1. Immunotherapy approaches in the treatment of malignant brain tumors

      Anastasie M. Dunn-Pirio and Gordana Vlahovic

      Version of Record online: 22 NOV 2016 | DOI: 10.1002/cncr.30371

      • image
      • image

      Despite current standard therapies, glioblastoma bears a dismal prognosis. Fortunately, a greater understanding of the complex interactions between the immune system and malignant gliomas, coupled with recent advances in immunotherapy for other cancers, have promoted research in immunotherapy for primary glial tumors that hopefully will shift to more positive outcomes.

  14. Original Articles

    1. Discipline

      Pediatric Oncology
      Short-term and long-term effects of childhood cancer on income from employment and employment status: A national cohort study in Sweden

      Annika Lindahl Norberg, Scott M. Montgomery, Matteo Bottai, Mats Heyman and Emma I. Hovén

      Version of Record online: 21 NOV 2016 | DOI: 10.1002/cncr.30436

      • image
      • image

      Parents' income from employment and employment status are adversely affected by having a child with cancer, but the effects are not distributed equally. In particular, more support and financial assistance may be advocated for young parents, mothers with a lower educational level, and mothers who were born in another country.

    2. Disparities Research
      Addressing multilevel barriers to cervical cancer screening in Korean American women: A randomized trial of a community-based intervention

      Carolyn Y. Fang, Grace X. Ma, Elizabeth A. Handorf, Ziding Feng, Yin Tan, Joanne Rhee, Suzanne M. Miller, Charles Kim and Han Seung Koh

      Version of Record online: 21 NOV 2016 | DOI: 10.1002/cncr.30391

      Korean American women experience numerous access and linguistic barriers to cervical cancer screening and have one of the lowest rates of screening relative to other US subgroups. A multicomponent, community-based intervention that combined cancer education with the delivery of key navigation services is highly effective in increasing cervical cancer screening rates in this underserved population.

    3. Survivorship
      Mental distress and health care use among survivors of adolescent and young adult cancer: A cross-sectional analysis of the National Health Interview Survey

      Sapna Kaul, Jaqueline C. Avila, Miriam Mutambudzi, Heidi Russell, Anne C. Kirchhoff and Cindy L. Schwartz

      Version of Record online: 17 NOV 2016 | DOI: 10.1002/cncr.30417

      • image

      In the current study, greater than 30% of survivors of adolescent and young adult cancer reported nonspecific moderate or severe mental distress versus 20% of a comparison group. Only 14% of survivors reported having seen a mental health professional within the previous year. Moreover, 75% and 52% of survivors with moderate and severe distress, respectively, had not talked to a mental health professional within the previous year.

    4. Disease Site

      Gynecologic Oncology
      What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study

      Bunja J. Rungruang, Austin Miller, Thomas C. Krivak, Neil S. Horowitz, Noah Rodriguez, Chad A. Hamilton, Floor J. Backes, Linda F. Carson, Michael Friedlander, David G. Mutch, Michael J. Goodheart, Krishnansu S. Tewari, Robert M. Wenham, Michael A. Bookman, G. Larry Maxwell and Scott D. Richard

      Version of Record online: 16 NOV 2016 | DOI: 10.1002/cncr.30414

      • image
      • image
      • image
      • image
      • image

      Retroperitoneal exploration in optimally debulked stage IIIC ovarian cancer patients is associated with improved progression-free and overall survival. Our data suggest that when minimal or no gross residual is achieved, a retroperitoneal nodal exploration should be performed.

  15. Correspondence

  16. Review Articles

    1. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?

      Scott M. Haake and W. Kimryn Rathmell

      Version of Record online: 14 NOV 2016 | DOI: 10.1002/cncr.30314

      • image

      Discovery in the treatment of the renal cell carcinomas can be approached in 2 ways: by splitting tumor types along histologic and molecular features, coupling highly precision-focused therapy with a subset of disease with potential for benefit, or by lumping the various biologies and histologies together to include the rarer renal cell carcinoma types with more common diseases.

  17. Correspondence

    1. Patients with delirium and advanced solid cancer in the emergency department: A challenge for the emergency practitioner, oncologist, and intensivist

      François Vincent, Ida Pavese, Joseph Gligorov, Emmanuelle Zamparini and Caroline Bornstain

      Version of Record online: 14 NOV 2016 | DOI: 10.1002/cncr.30452

  18. Original Articles

    1. Discipline

      Clinical Trials
      Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study

      Pat Gulhati, Kanwal Raghav, Rachna T. Shroff, Gauri R. Varadhachary, Scott Kopetz, Milind Javle, Wei Qiao, Huamin Wang, Jeffrey Morris, Robert A. Wolff and Michael J. Overman

      Version of Record online: 14 NOV 2016 | DOI: 10.1002/cncr.30445

      • image
      • image

      The results of the current study demonstrate that the combination of capecitabine and oxaliplatin with bevacizumab is a safe and effective regimen for the treatment of patients with advanced small bowel adenocarcinoma and ampullary adenocarcinoma, with an overall response rate of 48.3%, a median progression-free survival of 8.7 months, and a median overall survival of 12.9 months. To the authors' knowledge, this is the first prospective clinical trial evaluating the use of targeted therapies in patients with small bowel adenocarcinoma and ampullary adenocarcinoma.

  19. Correspondence

  20. Original Articles

    1. Discipline

      Outcomes Research
      The impact of health insurance on cancer care in disadvantaged communities

      Zaid M. Abdelsattar, Samantha Hendren and Sandra L. Wong

      Version of Record online: 14 NOV 2016 | DOI: 10.1002/cncr.30431

      • image
      • image

      Individuals from disadvantaged communities are among the millions of uninsured Americans gaining insurance under the Affordable Care Act. This study examines whether health insurance and better access to care can mitigate the effects of the social determinants of health on cancer care for the leading 4 causes of cancer deaths in the United States.

  21. Editorial

    1. Responding to the quality imperative to embed mental health care into ambulatory oncology

      Frank J. Penedo and David Cella

      Version of Record online: 10 NOV 2016 | DOI: 10.1002/cncr.30402

      The calls by the Institute of Medicine to fully integrate psychosocial care into oncology practice are closer to being implemented. Because of the multiple challenges faced across the cancer care continuum, it is recommended that multidimensional approaches that extend beyond the assessment of depression and anxiety and consider physical symptoms and practical concerns be considered as part of systematic psychosocial screening in oncology practice. See also pages 000-000.

  22. Original Articles

    1. Discipline

      Psychosocial Oncology
      Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial

      Lynne I. Wagner, Stephanie L. Pugh, William Small Jr, Jeffrey Kirshner, Kulbir Sidhu, Martin J. Bury, Albert S. DeNittis, Tracy E. Alpert, Binh Tran, Beatrice F. Bloom, Julie Mai, Alexander Yeh, Kalika Sarma, Mark Becker, Jennifer James and Deborah Watkins Bruner

      Version of Record online: 10 NOV 2016 | DOI: 10.1002/cncr.29969

      • image
      • image
      • image

      Addressing psychosocial needs has been increasingly recognized as an integral component of quality cancer care, and the association between depression and cancer outcomes underscores the importance of identifying effective strategies for the detection of mood disorders among survivors. The 2-item Patient Health Questionnaire demonstrates good psychometric properties for screening patients for mood disorders, which are equivalent to the longer 9-item Patient Health Questionnaire and superior to the National Comprehensive Cancer Network Distress Thermometer. See also pages 000–000.

  23. Review Articles

    1. The challenges of tumor genetic diversity

      Edmund A. Mroz and James W. Rocco

      Version of Record online: 8 NOV 2016 | DOI: 10.1002/cncr.30430

      • image
      • image
      • image
      • image

      Genomic analyses over the past decade have documented the diversity of tumors both among patients and within individual patients' tumors. Both types of diversity pose challenges for therapy that oncology research and practice must address.

  24. Original Articles

    1. Discipline

      Epidemiology
      Prediagnostic alcohol consumption and colorectal cancer survival: The Colon Cancer Family Registry

      Amanda I. Phipps, Jamaica R. Robinson, Peter T. Campbell, Aung Ko Win, Jane C. Figueiredo, Noralane M. Lindor and Polly A. Newcomb

      Version of Record online: 8 NOV 2016 | DOI: 10.1002/cncr.30446

      Using data from the population-based Colon Cancer Family Registry, this study assesses whether colorectal cancer survival varies with patterns of prediagnostic alcohol consumption. The consumption of wine, but not other alcoholic beverages, is modestly associated with a better prognosis.

    2. Radiation Oncology
      The role of adjuvant radiotherapy in pathologically lymph node positive prostate cancer

      Naresh Jegadeesh, Yuan Liu, Chao Zhang, Jim Zhong, Richard J. Cassidy, Theresa Gillespie, Omer Kucuk, Peter Rossi, Viraj A. Master, Mehrdad Alemozaffar and Ashesh B. Jani

      Version of Record online: 8 NOV 2016 | DOI: 10.1002/cncr.30373

      • image
      • image

      Adjuvant radiotherapy with androgen deprivation is associated with improved overall survival in patients with lymph node-positive prostate cancer after prostatectomy. This correlation exists across all tested subgroups.

    3. Disease Site

      Breast Disease
      Effect of hospital volume on processes of breast cancer care: A National Cancer Data Base study

      Tina W. F. Yen, Liliana E. Pezzin, Jianing Li, Rodney Sparapani, Purushuttom W. Laud and Ann B. Nattinger

      Version of Record online: 8 NOV 2016 | DOI: 10.1002/cncr.30413

      • image

      The specific processes of care that mediate the volume–survival relationship in breast cancer remain to be identified. Within the National Cancer Database, women treated at higher-volume hospitals were more likely to have their cancer diagnosed before initial surgery and receive appropriate locoregional treatment (negative surgical margins and radiation therapy) but not more likely to receive appropriate systemic treatment.

  25. Editorial

    1. Lymph node-positive prostate cancer—From middle child to the new frontier

      Ronald C. Chen

      Version of Record online: 8 NOV 2016 | DOI: 10.1002/cncr.30374

      Retrospective data suggest that aggressive treatment can lead to long-term survival in patients who have lymph node-positive prostate cancer. This is an understudied group of patients, and prospective clinical trials are needed. See also pages 000–000.

  26. Original Articles

    1. Discipline

      Epidemiology
      Metabolic syndrome and risk of esophageal adenocarcinoma in elderly patients in the United States: An analysis of SEER-Medicare data

      Jennifer Drahos, Winnie Ricker, Ruth M. Pfeiffer and Michael B. Cook

      Version of Record online: 8 NOV 2016 | DOI: 10.1002/cncr.30365

      Metabolic syndrome appears to be associated with an increased risk of esophageal adenocarcinoma in males without gastroesophageal reflux disease and females regardless of gastroesophageal reflux disease status in the Surveillance, Epidemiology, and End Results-Medicare-linked database. Metabolic syndrome may impact the risk of esophageal adenocarcinoma primarily by increasing the risk of the precursor lesion Barrett esophagus.

  27. Editorial

    1. Omitting lymphadenectomy in patients with endometrial cancer

      Jean A. Hurteau

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30346

      Lymphadenectomy can be omitted for patients with endometrial cancer. See referenced original article and related editorial on pages 000-000 and 000-000.

  28. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment

      Andreza A. Senerchia, Carla Renata Macedo, Sima Ferman, Marcelo Scopinaro, Walter Cacciavillano, Erica Boldrini, Vera Lúcia Lins de Moraes, Guadalupe Rey, Claudia T. de Oliveira, Luis Castillo, Maria Tereza Almeida, Maria Luisa Borsato, Eduardo Lima, Daniel Lustosa, José Henrique Barreto, Tatiana El-Jaick, Simone Aguiar, Algemir Brunetto, Lauro Greggiani, Hugo Cogo-Moreira, Alvaro Atallah and Antonio Sergio Petrilli

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30411

      • image
      • image
      • image

      Because preclinical models have shown that metronomic chemotherapy may be effective against chemotherapy-resistant tumors, the potential effect of metronomic chemotherapy with continuous oral cyclophosphamide and methotrexate in patients with high-grade operable osteosarcomas of the extremities has been investigated. The current event-free survival results do not support the routine use of cyclophosphamide and methotrexate as metronomic agents after standard chemotherapy for osteosarcoma. However, these results should not preclude further investigation into the potential of maintenance for patients with osteosarcomas.

    2. Gastrointestinal Disease
      Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database

      Brett L. Ecker, Matthew T. McMillan, Jashodeep Datta, Major K. Lee, Giorgos C. Karakousis, Charles M. Vollmer Jr, Jeffrey A. Drebin, Douglas L. Fraker and Robert E. Roses

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30439

      • image
      • image
      • image
      • image

      Optimal adjuvant approaches for resected duodenal adenocarcinoma are not well established, and there may be a subset of patients who benefit from the addition of radiotherapy to an adjuvant chemotherapy regimen. Using propensity score-matched analysis of patients with resected, nonmetastatic, duodenal adenocarcinoma who were identified in the National Cancer Data Base, the authors report that chemoradiotherapy does not appear to be associated with improvements in overall survival compared with chemotherapy.

    3. Gynecologic Oncology
      Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC)

      Jennifer M. Scalici, Sanja Arapovic, Erin J. Saks, Kristen A. Atkins, Gina Petroni, Linda R. Duska and Jill K. Slack-Davis

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30415

      • image
      • image
      • image
      • image
      • image

      Expression of vascular cell adhesion molecule-1 (VCAM-1) on the mesothelium is a predictor of ovarian cancer treatment response and prognosis as its presence correlates with platinum sensitivity, progression of disease, and overall survival, affirming that the presence of VCAM-1 in the tumor microenvironment of EOC appears to be pivotal in determining the biologic behavior of disease. Soluble serum VCAM-1 does not correlate with mesothelium expression in this small pilot study.

    4. Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study

      Sokbom Kang, Joo-Hyun Nam, Duk-Soo Bae, Jae-Weon Kim, Moon-Hong Kim, Xiaojun Chen, Jae-Hong No, Jong-Min Lee, Jae-Hoon Kim, Hidemich Watari, Seok Mo Kim, Sung Hoon Kim, Seok Ju Seong, Ki Tae Kim, Seung Cheol Kim, Jong-Hyeok Kim, Myung-Cheol Lim, Jung-Yun Lee, Sang-Young Ryu, Bingyi Yang and Byoung-Gie Kim

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30349

      • image
      • image

      An international, multicenter study has confirmed that endometrial cancer patients with a low risk for lymph node metastasis can be identified before surgery with a prediction model including magnetic resonance imaging and serum biomarker levels. The results of this study will facilitate presurgical counseling and treatment decision making. See editorials on pages 000-000 and 000-000.

  29. Editorial

    1. Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery

      David Scott Miller

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30418

      There is no advantage to ignoring occult lymphatic metastases in endometrial cancer. There are a variety of strategies available to the surgeon to help in identifying patients at higher risk for lymphatic metastasis who are more likely to benefit from lymphadenectomy. See referenced original article and related editorial on pages 000-000 and 000-000.

  30. Original Articles

    1. Discipline

      Translational Research
      Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model

      Jane J. Keating, Jeffrey J. Runge, Sunil Singhal, Sarah Nims, Ollin Venegas, Amy C. Durham, Gary Swain, Shuming Nie, Philip S. Low and David E. Holt

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30419

      • image
      • image
      • image
      • image
      • image

      Folate-targeted near-infrared imaging allows the intraoperative fluorescent imaging of pulmonary tumors and regional disease. This study lays the groundwork for a larger ongoing clinical human trial.

    2. Epidemiology
      Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment

      Archana Radhakrishnan, David Grande, Nandita Mitra, Justin Bekelman, Christian Stillson and Craig Evan Pollack

      Version of Record online: 7 NOV 2016 | DOI: 10.1002/cncr.30412

      • image

      Although a large proportion of men obtain second opinions from urologists, these visits are not associated with treatment choice or quality of prostate cancer care. Additional studies are needed to determine the role of second opinions in promoting high-quality cancer care.

  31. Review Articles

    1. Non–muscle-invasive bladder cancer: Intravesical treatments beyond bacille Calmette-Guérin

      Vignesh T. Packiam, Scott C. Johnson and Gary D. Steinberg

      Version of Record online: 2 NOV 2016 | DOI: 10.1002/cncr.30392

      • image

      An unmet need continues to exist for patients with high-risk non–muscle-invasive bladder cancer for whom bacille Calmette-Guérin has failed and who seek further bladder-sparing approaches. This review explores the role of emerging intravesical therapies.

  32. Original Articles

    1. Disease Site

      Hematologic Malignancies
      HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia

      Bettina Wagner, Fabiola da Silva Nardi, Sabine Schramm, Thomas Kraemer, Alexander A. Celik, Jan Dürig, Peter A. Horn, Ulrich Dührsen, Holger Nückel and Vera Rebmann

      Version of Record online: 2 NOV 2016 | DOI: 10.1002/cncr.30427

      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image

      In a cohort of 110 individuals with chronic lymphocytic leukemia, human leukocyte antigen-E (HLA-E)*01:03 alleles and high levels of soluble HLA-E are significantly associated with an early treatment requirement. HLA-E alleles and soluble HLA-E levels may represent novel biomarkers for early disease progression in patients with chronic lymphocytic leukemia.

    2. Discipline

      Pediatric Oncology
      Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database

      Benjamin W. Fischer-Valuck, Ishita Chen, Amar J. Srivastava, John M. Floberg, Yuan James Rao, Allison A. King, Eric T. Shinohara and Stephanie M. Perkins

      Version of Record online: 2 NOV 2016 | DOI: 10.1002/cncr.30405

      • image
      • image

      In the treatment of atypical teratoid rhabdoid tumors, trimodality therapy (surgery, chemotherapy, and radiation therapy) has significantly increased in recent years and is associated with improved overall survival. For patients with localized atypical teratoid rhabdoid tumors who receive trimodality therapy, the 5-year overall survival rate approaches 50%.

  33. Review Articles

    1. Needle tract seeding after percutaneous biopsy of sarcoma: Risk/benefit considerations

      David Berger-Richardson and Carol J. Swallow

      Version of Record online: 2 NOV 2016 | DOI: 10.1002/cncr.30370

      • image

      The pretreatment diagnosis and classification of sarcoma typically entails open, Tru-Cut, or percutaneous core needle biopsy. Delineation of the tumor subtype and grade permits optimal pretreatment decision making and the tailored use of multimodality therapy, benefits that outweigh the very small risk of needle tract seeding after percutaneous biopsy.

  34. Original Articles

    1. Disease Site

      Endocrine Disease
      Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis

      Yash R. Somnay, Xiao-Min Yu, Ricardo V. Lloyd, Glen Leverson, Zviadi Aburjania, Samuel Jang, Renata Jaskula-Sztul and Herbert Chen

      Version of Record online: 2 NOV 2016 | DOI: 10.1002/cncr.30403

      • image
      • image
      • image
      • image
      • image
      • image

      Expression of the Notch family's third isoform (Notch3) is progressively lost across lesser differentiated, more malignant thyroid cancer subtypes, and correlates directly with disease prognosis. Conversely, activation of Notch3 suppresses thyroid cancer cell proliferation and upregulates thyroid-specific differentiated features. These findings warrant further investigation into therapeutic targeting of Notch3 for treating advanced disease.

  35. Review Articles

    1. Prostate cancer: Developing novel approaches to castration-sensitive disease

      Edoardo Francini and Mary-Ellen Taplin

      Version of Record online: 1 NOV 2016 | DOI: 10.1002/cncr.30329

      • image

      Multimodality approaches including chemotherapy and novel hormonal agents are frequently investigated in early-stage prostate cancer with the aim of maximizing the response efficacy and duration for patients with castration-sensitive disease. Immunotherapy and experimental molecules are also being actively explored in this setting.

  36. Original Articles

    1. Disease Site

      Genitourinary Disease
      Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

      Eric Ojerholm, Andrew Smith, Wei-Ting Hwang, Brian C. Baumann, Kai N. Tucker, Seth P. Lerner, Ronac Mamtani, Ben Boursi and John P. Christodouleas

      Version of Record online: 27 OCT 2016 | DOI: 10.1002/cncr.30422

      • image

      This is the first category B biomarker study testing the neutrophil-to-lymphocyte ratio in bladder cancer. In contrast to previous reports, these data suggest that the neutrophil-to-lymphocyte ratio holds neither prognostic nor predictive value for overall survival.

    2. Discipline

      Outcomes Research
      Results of a randomized controlled trial to increase cervical cancer screening among rural Latinas

      Beti Thompson, Elizabeth A. Carosso, Esther Jhingan, Lei Wang, Sarah E. Holte, Theresa L. Byrd, Maria C. Benavides, Cathy Lopez, Javiera Martinez-Gutierrez, Genoveva Ibarra, Virginia J. Gonzalez, Nora E. Gonzalez and Catherine R. Duggan

      Version of Record online: 27 OCT 2016 | DOI: 10.1002/cncr.30399

      • image

      Latinas out of compliance with cervical cancer screening were randomized to usual care, a low-intensity intervention, or a high-intensity intervention to increase cervical cancer screening. The high-intensity intervention is effective and cost-effective.

    3. Disease Site

      Neuro-Oncology
      Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report

      Florien W. Boele, Charles W. Given, Barbara A. Given, Heidi S. Donovan, Richard Schulz, Jason M. Weimer, Jan Drappatz, Frank S. Lieberman and Paula R. Sherwood

      Version of Record online: 27 OCT 2016 | DOI: 10.1002/cncr.30428

      • image

      In the current study, the authors investigate whether caregivers' anxiety, depressive symptoms, burden, and mastery influence survival in a sample of patients newly diagnosed with glioblastoma multiforme. After controlling for known covariates, caregiver mastery appears to be predictive of patient survival.

    4. Breast Disease
      Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry

      N. Lynn Henry, Thomas M. Braun, Haythem Y. Ali, Khan Munir, Samuel M. Silver, David H. Gorski, Tara M. Breslin and Jennifer J. Griggs

      Version of Record online: 27 OCT 2016 | DOI: 10.1002/cncr.30429

      • image
      • image
      • image

      Since 2006, use of the 21-gene recurrence score assay has appeared to be associated with a reduction in the receipt of chemotherapy in patients with lymph node-negative and lymph node-positive, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Use of the recurrence score assay also has been found to be associated with a reduction in the receipt of anthracycline-containing chemotherapy regimens regardless of lymph node status.

  37. Review Articles

    1. Posterior fossa syndrome: Review of the behavioral and emotional aspects in pediatric cancer patients

      Jane C. Lanier and Annah N. Abrams

      Version of Record online: 27 OCT 2016 | DOI: 10.1002/cncr.30238

      • image
      • image

      Posterior fossa syndrome is a constellation of impairing and distressing symptoms, including mutism, ataxia/hypotonia, and emotional lability, that develop in approximately 25% of children after the surgical resection of posterior fossa tumors. The identification and treatment of children with posterior fossa syndrome can lead to improvements in their overall quality of life.

  38. Communication

    1. You have full text access to this OnlineOpen article
      Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries

      The National Cancer Institute Surveillance, Epidemiology, and End Results Prostate-Specific Antigen Working Group, Margaret (Peggy) Adamo, Jessica A. Boten, Linda M. Coyle, Kathleen A. Cronin, Clara J. K. Lam, Serban Negoita, Lynne Penberthy, Jennifer L. Stevens and Kevin C. Ward

      Version of Record online: 26 OCT 2016 | DOI: 10.1002/cncr.30401

      Researchers have used prostate-specific antigen (PSA) values collected by central cancer registries to evaluate tumors for potential aggressive clinical disease. The current study describes the comprehensive review of PSA laboratory values recorded across all Surveillance, Epidemiology, and End Results registries for 2012 prostate cancer cases and the proposed mechanism for reviewing and correcting PSA laboratory values.

  39. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Database

      Richard J. Cassidy, Yuan Liu, Kirtesh Patel, Jim Zhong, Conor E. Steuer, David A. Kooby, Maria C. Russell, Theresa W. Gillespie and Jerome C. Landry

      Version of Record online: 25 OCT 2016 | DOI: 10.1002/cncr.30410

      • image
      • image
      • image

      Because the selective elimination of neoadjuvant radiation for stage II/III rectal adenocarcinomas is evolving, the National Cancer Data Base is used to identify US practice patterns, to determine predictors of receiving neoadjuvant multiagent chemotherapy versus traditional neoadjuvant chemoradiotherapy, and to identify factors associated with overall survival. The results indicate that eliminating radiation produces worse survival outcomes, and radiation should not be omitted outside of a clinical trial.

    2. Breast Disease
      Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ

      Hui Zhao, Nainan Hei, Yiling Wu, Winston Chan, Xiudong Lei, Carrie Cameron, Shine Chang, Mariana Chavez-MacGregor and Sharon H. Giordano

      Version of Record online: 25 OCT 2016 | DOI: 10.1002/cncr.30425

      • image
      • image

      Older women with ductal carcinoma in situ treated with tamoxifen or aromatase inhibitors have a low rate of adherence to treatment over a 5-year period after surgery. This population-based study reveals key factors associated with treatment initiation for elderly patients with ductal carcinoma in situ.

    3. Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer

      Christopher R. Friese, Yun Li, Irina Bondarenko, Timothy P. Hofer, Kevin C. Ward, Ann S. Hamilton, Dennis Deapen, Allison W. Kurian and Steven J. Katz

      Version of Record online: 24 OCT 2016 | DOI: 10.1002/cncr.30324

      • image
      • image
      • image
      • image

      In a population-based sample of women diagnosed with early-stage breast cancer, the majority of women, including a third of women with lymph node–positive disease, received 21-gene recurrence score testing. The test results correlated with guideline-recommended treatment in most cases, and patient satisfaction was high.

    4. Melanoma
      You have full text access to this OnlineOpen article
      An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi

      Loren E. Clarke, Darl D. Flake II, Klaus Busam, Clay Cockerell, Klaus Helm, Jennifer McNiff, Jon Reed, Jaime Tschen, Jinah Kim, Raymond Barnhill, Rosalie Elenitsas, Victor G. Prieto, Jonathan Nelson, Hillary Kimbrell, Kathryn A. Kolquist, Krystal L. Brown, M. Bryan Warf, Benjamin B. Roa and Richard J. Wenstrup

      Version of Record online: 21 OCT 2016 | DOI: 10.1002/cncr.30385

      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image

      A 23-gene signature has recently been developed to differentiate malignant and benign melanocytic lesions. This study shows that the gene expression signature differentiates benign nevi from malignant melanoma with a sensitivity of 91.5% and a specificity of 92.5% in comparison with a triple-concordant histopathologic review.

    5. Discipline

      Survivorship
      Impact of chronic disease on emotional distress in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study

      Stefanie C. Vuotto, Kevin R. Krull, Chenghong Li, Kevin C. Oeffinger, Daniel M. Green, Sunita K. Patel, Deokumar Srivastava, Marilyn Stovall, Kirsten K. Ness, Gregory T. Armstrong, Leslie L. Robison and Tara M. Brinkman

      Version of Record online: 20 OCT 2016 | DOI: 10.1002/cncr.30348

      • image
      • image

      Survivors who have been exposed to cancer-directed therapies in childhood are at an increased risk of developing cardiac, endocrine, and pulmonary chronic health conditions. These chronic health conditions contribute to emotional distress symptoms in adult survivors of childhood cancer.

    6. Clinical Trials
      Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study

      Carsten-O. Sahlmann, Kia Homayounfar, Martin Niessner, Jerzy Dyczkowski, Lena-Christin Conradi, Friederike Braulke, Birgit Meller, Tim Beißbarth, B. Michael Ghadimi, Johannes Meller, David M. Goldenberg and Torsten Liersch

      Version of Record online: 20 OCT 2016 | DOI: 10.1002/cncr.30390

      • image
      • image
      • image
      • image

      On the basis of the high prevalence of carcinoembryonic antigen (CEA) expression by colorectal tumor cells, repeated anti-CEA 131I-labetuzumab radioimmunotherapy is investigated in the adjuvant setting after complete resection of colorectal liver metastases when occult microscopic disease is expected. The treatment is feasible but is associated with hematotoxicity; and, although survival is very encouraging, particularly for “truly adjuvant” patients, the maximum safe dose of 131I-labetuzumab is a single administration of 50 mCi/m2.

    7. Disease Site

      Hematologic Malignancies
      Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

      Paul B. Koller, Hagop M. Kantarjian, Graciela M. Nogueras-Gonzalez, Elias Jabbour, Srdan Verstovsek, Gautam Borthakur, Zeev Estrov, William G. Wierda, Guillermo Garcia-Manero, Alessandra Ferrajoli, Farhad Ravandi, Susan M. O'Brien and Jorge E. Cortes

      Version of Record online: 20 OCT 2016 | DOI: 10.1002/cncr.30362

      • image
      • image

      The authors report on a group of patients with chronic myeloid leukemia in chronic phase who were treated with tyrosine kinase inhibitors and who had a prior history of another malignancy. The results suggest these patients have the same excellent outcomes for chronic myeloid leukemia as those who do not have a prior malignancy.

    8. Discipline

      Survivorship
      The experience of treatment barriers and their influence on quality of life in American Indian/Alaska Native breast cancer survivors

      Elizabeth A. Goodwin, Linda Burhansstipanov, Mark Dignan, Katherine L. Jones and Judith Salmon Kaur

      Version of Record online: 20 OCT 2016 | DOI: 10.1002/cncr.30406

      The social quality of life for American Indian/Alaska Native breast cancer survivors is significantly affected when they encounter 5 or more barriers to accessing initial cancer treatment. More barriers are encountered during cancer treatment than when accessing care, except for those who are uninsured or who use public care and those who report that they have one-half or less American Indian/Alaska Native blood.

    9. Translational Research
      Dynamic optical contrast imaging as a novel modality for rapidly distinguishing head and neck squamous cell carcinoma from surrounding normal tissue

      Bobby A. Tajudeen, Zachary D. Taylor, James Garritano, Harrison Cheng, Aidan Pearigen, Adria J. Sherman, Fernando Palma-Diaz, Pratik Mishra, Siddharth Bhargava, Julianna Pesce, Irene Kim, Christine Sebastian, Ali Razfar, Asael Papour, Oscar Stafsudd, Warren Grundfest and Maie St. John

      Version of Record online: 20 OCT 2016 | DOI: 10.1002/cncr.30338

      • image
      • image
      • image
      • image
      • image

      Dynamic optical contrast imaging is a novel technology based on unique optical properties that rapidly and accurately distinguish head and neck squamous cell carcinoma from surrounding normal tissue. An analysis of dynamic optical contrast imaging reveals microscopic characterization sufficient for tissue-type identification consistent with histology.

    10. Radiation Oncology
      Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors

      Vivek Verma, Valerie K. Shostrom, Sameera S. Kumar, Weining Zhen, Christopher L. Hallemeier, Steve E. Braunstein, John Holland, Matthew M. Harkenrider, Adrian S. Iskhanian, Hanmanth J. Neboori, Salma K. Jabbour, Albert Attia, Percy Lee, Fiori Alite, Joshua M. Walker, John M. Stahl, Kyle Wang, Brian S. Bingham, Christina Hadzitheodorou, Roy H. Decker, Ronald C. McGarry and Charles B. Simone II

      Version of Record online: 14 OCT 2016 | DOI: 10.1002/cncr.30375

      • image

      To the authors' knowledge, the current study is the largest published to date to examine stereotactic body radiotherapy for patients with non-small cell lung tumors measuring ≥5 cm. This multi-institutional analysis demonstrates that stereotactic body radiotherapy is a safe and efficacious option for these patients.

  40. Correspondence

    1. Reply to high hepatocellular carcinoma risk among US-born Hispanics

      V. Wendy Setiawan, Pengxiao C. Wei, Brenda Y. Hernandez, Shelly C. Lu, Kristine R. Monroe, Loic Le Marchand and Jian Min Yuan

      Version of Record online: 14 OCT 2016 | DOI: 10.1002/cncr.30396

  41. Commentary

    1. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?

      Bryan R. Haugen

      Version of Record online: 14 OCT 2016 | DOI: 10.1002/cncr.30360

      • image
      • image
      • image

      The 2015 American Thyroid Association guidelines for the treatment of adults with thyroid nodules and differentiated thyroid cancer have changed significantly from previous guidelines. Some of the major changes concern sonographic risk patterns for thyroid nodules, the use of “response to therapy” to help to guide long-term management, and a new section regarding the management of patients with radioactive iodine-refractory differentiated thyroid cancer.

  42. Correspondence

    1. High hepatocellular carcinoma risk among US-born Hispanics

      Antonio Ponzetto and Natale Figura

      Version of Record online: 14 OCT 2016 | DOI: 10.1002/cncr.30397

  43. Original Articles

    1. Discipline

      Clinical Trials
      Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

      Elias Jabbour, Stefan Faderl, Koji Sasaki, Tapan Kadia, Naval Daver, Naveen Pemmaraju, Keyur Patel, Joseph D. Khoury, Carlos Bueso-Ramos, Zachary Bohannan, Farhad Ravandi, Gautam Borthakur, Srdan Verstovsek, Darla Miller, Rita Maduike, Chitra Hosing, Hagop M. Kantarjian and Guillermo Garcia-Manero

      Version of Record online: 14 OCT 2016 | DOI: 10.1002/cncr.30383

      • image
      • image

      The effectiveness of low-dose clofarabine and cytarabine in higher risk myelodysplastic syndrome patients after hypomethylating agent failure is assessed. This dose combination is clinically active in these patients (especially those with diploid cytogenetics) and may be useful as a bridge to allogeneic stem cell transplantation in eligible patients.

    2. Disease Site

      Gastrointestinal Disease
      Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases

      Timothy L. Frankel, Efsevia Vakiani, Hari Nathan, Ronald P. DeMatteo, T. Peter Kingham, Peter J. Allen, William R. Jarnagin, Nancy E. Kemeny, David B. Solit and Michael I. D'Angelica

      Version of Record online: 13 OCT 2016 | DOI: 10.1002/cncr.30351

      • image
      • image
      • image
      • image
      • image
      • image

      The authors sought to determine whether the location of driver mutations within the RAS oncogene impacts the biology of metastatic colorectal cancer. After stratifying patients by the exon location of mutation, dramatic differences are observed in both survival and pathologic features.

    3. Discipline

      Pediatric Oncology
      Difficult relationships between parents and physicians of children with cancer: A qualitative study of parent and physician perspectives

      Jennifer W. Mack, Maya Ilowite and Sarah Taddei

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30395

      Difficult relationships between parents and physicians of children with cancer follow several common patterns, including problems of connection and understanding, confrontational parental advocacy, mental health issues, and structural challenges to care. Some challenges, such as problems of connection and understanding, offer an opportunity for healing, whereas others, such as confrontational advocacy, appear especially refractory to repair.

  44. Correspondence

    1. “Twistin' the night away”: Fertility preservation in young adult female cancer survivors

      Ernesto Zanet, Rosanna Ciancia, Mariagrazia Michieli and Umberto Tirelli

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30394

  45. Original Articles

    1. Disease Site

      Breast Disease
      Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014

      Laura M. Spring, Megan R. Marshall and Erica T. Warner

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30378

      • image

      From 2011 to 2014, fewer than one-half of women received provider communication regarding mammogram choice in the study population, despite the recommendations of the US Preventive Services Task Force. Provider communication concerning mammogram choice can influence screening behavior, particularly for women aged 40 to 49 years and those aged ≥70 years.

    2. Discipline

      Epidemiology
      Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study

      Judith S. Brand, Elham Hedayati, Nirmala Bhoo-Pathy, Jonas Bergh, Per Hall, Keith Humphreys, Jonas F. Ludvigsson and Kamila Czene

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30364

      • image
      • image

      Breast cancer patients are at highest risk for venous thromboembolism within the first year of their diagnosis, but the risk remains 2-fold increased for many years afterward. Temporal associations with patient, tumor, and treatment characteristics provide insight into the time-dependent etiology of venous thromboembolism in breast cancer patients.

  46. Correspondence

    1. Reply to “Twistin' the night away”: Fertility preservation in young adult female cancer survivors

      Catherine Benedict, Bridgette Thom, Danielle N. Friedman, Debbie Diotallevi, Elaine M. Pottenger, Nirupa J. Raghunathan and Joanne F. Kelvin

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30389

  47. Editorial

    1. The Affordable Care Act, or Obamacare, 3 years later: A reality check

      Hagop M. Kantarjian

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30384

      Enacted 3 years ago, the Patient Protection and Affordable Care Act continues to be the subject of intense discussions and controversy. Herein, the progress in health care promulgated by implementation of the Patient Protection and Affordable Care Act is reviewed, persistent issues and unforeseen consequences discussed, and remedial solutions proposed.

  48. Original Articles

    1. Disease Site

      Genitourinary Disease
      A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma

      Sumanta K. Pal, Harry A. Drabkin, James A. Reeves, John D. Hainsworth, Susan E. Hazel, Dario A. Paggiarino, Jon Wojciak, Gary Woodnutt and Rupal S. Bhatt

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30393

      • image
      • image
      • image
      • image
      • image

      In the current study, the authors assess the activity of sonepcizumab, a first-in-class sphingosine-1-phosphate inhibitor, within the context of previously treated patients with renal cell carcinoma. The encouraging overall survival and safety profile associated with this agent make it valid for further study.

    2. Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men

      Mehmet I. Gökce, Xuemei Wang, Jacqueline Frost, Pamela Roberson, Robert J. Volk, Durado Brooks, Steven E. Canfield and Curtis A. Pettaway

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30367

      The American Cancer Society Decision Aid, delivered in the form of a presentation, is a good model for patient education and informed decision making in a population of medically underserved men. The increase in prostate cancer knowledge associated with presentation of this decision aid is correlated with low levels of decisional conflict for prostate cancer screening.

    3. Head and Neck Disease
      A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis

      William A. Stokes, Bernard L. Jones, Shilpa Bhatia, Ayman J. Oweida, Daniel W. Bowles, David Raben, Julie A. Goddard, Jessica D. McDermott and Sana D. Karam

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30382

      • image
      • image
      • image
      • image

      Although laryngectomy is the treatment of choice for patients with T4 laryngeal cancer, many patients pursue larynx preservation, instead. In this National Cancer Data Base analysis, survival with an organ-preservation approach consisting of radiotherapy plus induction chemotherapy did not differ significantly from that with standard-of-care laryngectomy plus radiotherapy.

  49. Commentary

    1. The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited

      Jay S. Cooper, Catherine Fortpied, Vincent Gregoire, Quynh-Thu Le, Thomas F. Pajak, Qiang (Ed) Zhang and Jacques Bernier

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30266

      • image
      • image

      A recent review in this journal in which the National Comprehensive Cancer Network's recommendations (based in part on results from the Radiation Therapy Oncology Group 9501 and European Organization for Research and Treatment of Cancer 22931 trials) were criticized warrants comment. To address many of the points and misinterpretations raised in that review, additional data are provided that convincingly support the use of concomitant chemotherapy and radiotherapy in patients who have good performance status and high-risk pathologic features after surgery for mucosal head and neck squamous cell carcinoma.

  50. Original Articles

    1. Discipline

      Psychosocial Oncology
      You have full text access to this OnlineOpen article
      Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity

      Jonas A. de Souza, Bonnie J. Yap, Kristen Wroblewski, Victoria Blinder, Fabiana S. Araújo, Fay J. Hlubocky, Lauren H. Nicholas, Jeremy M. O’Connor, Bruce Brockstein, Mark J. Ratain, Christopher K. Daugherty and David Cella

      Version of Record online: 7 OCT 2016 | DOI: 10.1002/cncr.30369

      • image

      The COmprehensive Score for financial Toxicity (COST) is validated in a novel sample of patients with cancer. Independent factors found to be associated with financial toxicity include race, employment, income, number of inpatient admissions, and psychological distress.

    2. Disease Site

      Soft Tissue and Bone Sarcoma
      Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

      Scott M. Schuetze, Vanessa Bolejack, Edwin Choy, Kristen N. Ganjoo, Arthur P. Staddon, Warren A. Chow, Hussein A. Tawbi, Brian L. Samuels, Shreyaskumar R. Patel, Margaret von Mehren, Gina D’Amato, Kirsten M. Leu, David M. Loeb, Charles A. Forscher, Mohammed M. Milhem, Daniel A. Rushing, David R. Lucas, Rashmi Chugh, Denise K. Reinke and Laurence H. Baker

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30379

      • image
      • image

      Dasatinib demonstrates no significant antisarcoma activity in patients with epithelioid sarcoma or solitary fibrous tumor. Patients with alveolar soft part sarcoma have prolonged disease progression–free and overall survival, but this is not necessarily caused by dasatinib. A small minority of patients with chondrosarcoma or chordoma experience an objective tumor response or prolonged stabilization of disease, and this suggests that dasatinib treatment should be further evaluated for these sarcoma subtypes. See also pages 000-000.

    3. Discipline

      Outcomes Research
      Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort

      Roxanne E. Jensen, Carol M. Moinpour, Arnold L. Potosky, Tania Lobo, Elizabeth A. Hahn, Ron D. Hays, David Cella, Ashley Wilder Smith, Xiao-Cheng Wu, Theresa H. M. Keegan, Lisa E. Paddock, Antoinette M. Stroup and David T. Eton

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30354

      This study presents strong evidence across multiple evaluation methods that Patient-Reported Outcomes Measurement Information System (PROMIS) measures are responsive to both improvements and declines in symptoms and function experienced by cancer patients. These findings will be able to inform the design and interpretation of future research studies and clinical initiatives administering PROMIS measures.

  51. Editorial

    1. You have full text access to this OnlineOpen article
      We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas

      Victor M. Villalobos, Brianna Hoffner and Anthony D. Elias

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30377

      Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well-defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 000-000.

  52. Original Articles

    1. Discipline

      Epidemiology
      Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience

      Kevin Junus, Maria Aguilar, Priya Patel, David Irwin, Stephen Yee, Benny Liu, Taft Bhuket and Robert J. Wong

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30381

      The risk of hepatitis B virus (HBV) reactivation or flare is high among patients with chronic HBV or previously resolved HBV treated with anti-CD20 therapies. Screening for HBV with both HBV surface antigen and HBV core antibody is important to prevent HBV flares or reactivation, which carry a high morbidity and mortality.

    2. Disease Site

      Hematologic Malignancies
      Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease

      Ghayas C. Issa, Hagop M. Kantarjian, C. Cameron Yin, Wei Qiao, Farhad Ravandi, Deborah Thomas, Nicholas J. Short, Koji Sasaki, Guillermo Garcia-Manero, Tapan M. Kadia, Jorge E. Cortes, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Issa Khouri, Partow Kebriaei, Richard E. Champlin, Sherry Pierce, Susan M. O’Brien and Elias Jabbour

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30376

      • image
      • image
      • image
      • image

      In adult patients with acute lymphoblastic leukemia, low hypodiploidy/near-triploidy and a complex karyotype are associated with worse survival independently of minimal residual disease response. Pretreatment cytogenetics should still be used for the risk stratification of patients with acute lymphoblastic leukemia.

    3. Gynecologic Oncology
      A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma

      Yifan Li, Jing Zeng, Manni Huang, Jusheng An, Ping Bai, Lingying Wu and Rong Zhang

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30328

      • image
      • image

      Cervical cancer is the third most common malignancy diagnosed in women, chemotherapy is the main treatment of patients with stage IVB recurrent or metastatic cervical cancer. The combination of nab-paclitaxel plus nedaplatin for the treatment of patients with late-stage, recurrent, or metastatic cervical cancer appears to be active and tolerable.

    4. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey

      Ruben A. Mesa, Carole B. Miller, Maureen Thyne, James Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, Wendy Wilson, Dilan C. Paranagama, David G. Dubinski, Ahmad Naim, Shreekant Parasuraman, John Boyle and John O. Mascarenhas

      Version of Record online: 30 SEP 2016 | DOI: 10.1002/cncr.30325

      • image
      • image
      • image
      • image

      This analysis of data from the myeloproliferative neoplasm (MPN) Landmark survey identified important gaps in patient and physician respondent perceptions about MPNs. Discordance in patient and physician respondent perceptions was observed in MPN-related prognostic risk assessment, symptom burden, treatment goals and expectations, and treatment satisfaction.

    5. The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results

      Federico G. Antillón, Jessica G. Blanco, Patricia D. Valverde, Mauricio Castellanos, Claudia P. Garrido, Veronica Girón, Tomas R. Letona, Emilia J. Osorio, Dyna A. Borrayo, Ricardo A. Mack, Mario A. Melgar, Rodolfo Lorenzana, Raul C. Ribeiro, Monika Metzger, Valentino Conter, Emanuela Rossi and Maria Grazia Valsecchi

      Version of Record online: 28 SEP 2016 | DOI: 10.1002/cncr.30257

      • image
      • image
      • image
      • image

      A well organized center in a low-middle–income country can overcome the barriers and treat children with acute lymphoblastic leukemia with a contemporary treatment protocol. Earlier diagnosis, better management of complications, and better knowledge of this disease will improve outcomes.

    6. Discipline

      Quality of Life
      Clinical presentation and outcomes for adult ependymoma patients

      Alvina A. Acquaye, Elizabeth Vera, Mark R. Gilbert and Terri S. Armstrong

      Version of Record online: 28 SEP 2016 | DOI: 10.1002/cncr.30355

      Implementing outcomes projects is feasible for ependymoma patients. Outcomes data help in understanding disease-related issues for this patient population.

    7. Disease Site

      Chest and Lung Disease
      Utilization of surgical treatment for local and locoregional esophageal cancer: Analysis of the National Cancer Data Base

      Lauren J. Taylor, Caprice C. Greenberg, Anne O. Lidor, Glen E. Leverson, James D. Maloney and Ryan A. Macke

      Version of Record online: 28 SEP 2016 | DOI: 10.1002/cncr.30368

      • image
      • image

      National use of potentially curative surgical treatment increased from 36.4% in 2004 to 47.4% in 2013 for patients with stage 0 to III esophageal cancer. The adoption of endoscopic local therapies has predominated for early-stage disease, whereas an encouraging increase in the use of esophagectomy for locoregional disease has been observed.

    8. Breast Disease
      The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort

      Sarah J. Nyante, Sheila S. Lee, Thad S. Benefield, Tiffany N. Hoots and Louise M. Henderson

      Version of Record online: 28 SEP 2016 | DOI: 10.1002/cncr.30281

      • image
      • image

      Mammographic calcifications appear to be associated with both favorable and unfavorable prognostic factors in patients with invasive breast cancer. Associations vary according to the calcification-specific Breast Imaging Reporting and Data System (BI-RADS) category, suggesting that the link between calcifications and prognosis depends on calcification type.

    9. Head and Neck Disease
      Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis

      Beth M. Beadle, Kai-Ping Liao, Sharon H. Giordano, Adam S. Garden, Katherine A. Hutcheson, Stephen Y. Lai and B. Ashleigh Guadagnolo

      Version of Record online: 23 SEP 2016 | DOI: 10.1002/cncr.30350

      • image

      The linked Surveillance, Epidemiology, and End Results-Medicare database is used to compare the rates and duration of feeding tube use in patients with head and neck cancers who receive intensity-modulated radiation therapy versus 3-dimensional radiation therapy. Patients who receive definitive intensity-modulated radiation therapy have similar rates of feeding tube placement but shorter duration of feeding tube use than those who receive 3-dimensional radiation therapy techniques.

    10. Discipline

      Radiation Oncology
      Association between access to accelerated partial breast irradiation and use of adjuvant radiotherapy

      Elyn H. Wang, Henry S. Park, Charles E. Rutter, Cary P. Gross, Pamela R. Soulos, James B. Yu and Suzanne B. Evans

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30356

      • image
      • image

      Facilities that offer partial breast irradiation are more likely to administer radiotherapy to women eligible for its omission. The availability of partial breast irradiation does not appear to improve compliance with radiation after lumpectomy.

    11. Disease Site

      Hematologic Malignancies
      Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

      Farhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, Elias Jabbour, Tapan Kadia, Sherry Pierce, Mark Brandt, Sa Wang, Sergej Konoplev, Xuemei Wang, Xuelin Huang, Naval Daver, Courtney DiNardo, Michael Andreeff, Marina Konopleva, Zeev Estrov, Guillermo Garcia-Manero, Jorge Cortes and Hagop Kantarjian

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30361

      • image
      • image
      • image

      Minimal residual disease assessment by multiparameter flow cytometry after induction and consolidation has significant prognostic value for patients with acute myeloid leukemia. According to a multivariate analysis, persistent minimal residual disease is the most important predictor of relapse-free and overall survival.

VIEW

  1. 1 - 100
  2. 101 - 129

SEARCH

SEARCH BY CITATION